These findings suggest that HSP60 down-regulation may be a pathological link and therapeutic target for AGEs-induced β-cell morphological and functional changes under diabetic hyperglycemia of early stage of T2D. This evidence concerns the gene HSPD1 and type 2 diabetes mellitus.